

Posted January 14, 2008

## **ImmunID Technologies signed a Service Research Contract with Sanofi Pasteur**

ImmunID Technologies announced today the signature of a Contract Research Service with Sanofi Pasteur, the vaccines division of sanofi-aventis Group, and the largest worldwide company entirely devoted to human vaccines.

**The innovative technology developed by ImmunID allows the assessment of Human T and B immune repertoires diversity after vaccination.**

« We are greatly pleased by the confidence Sanofi's teams placed in us. Our commune belonging to the Rhône Alpine Biocluster (LyonBiopôle), the increasing interest of Sanofi Pasteur in Innovative immunomonitoring solutions and in young Biotech companies, such as ImmunID, are important standards which have allowed the achievement of this agreement. » said Nicolas Pasqual CEO and co-founder of ImmunID Technologies.

“Our ImmunTraCkeR technology and our know how in immune repertoire analysis will contribute to measure the vaccine efficiency. We will use our expertise and our professionalism in order to make sure that this contract will be the first of a long list of Research Service Contract with pharmaceutical industry” followed Sébastien Weisbuch COO and co-founder of ImmunID Technologies.

### About ImmunID

ImmunID Technologies is a young Biotechnology company located in Grenoble, its mission is to develop and commercialise immunomonitoring tests dedicated to pharmaceutical industry and personalized medicine market.

ImmunID offers testing services to monitor the immune repertoire diversity in order to measure the impact of biotherapeutic molecules and to characterize more accurately their efficacy.

ImmunID develops diagnostic products for an early detection of immune related diseases.

Auteur : Nadia PLANTIER.